Arcellx announces oral presentation for its cart-ddbcma phase 1 trial in patients with relapsed or refractory multiple myeloma at the 65th ash annual meeting and exposition

-- abstract released today is from a june 2, 2023 data cut -- -- median duration of response, progression free survival, and overall survival rate not reached with median follow-up after cart-ddbcma infusion of 22 months -- -- a more recent data cut will be shared during the oral presentation with a median follow-up of 26.5 months -- -- company to host a live webcast event with an expert panel of clinicians -- redwood city, calif. , nov. 2, 2023 /prnewswire/ -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that new clinical data from its phase 1 study of cart-ddbcma in patients with relapsed or refractory multiple myeloma will be presented at the 65th american society of hematology (ash) annual meeting and exposition taking place december 9-12, 2023 in san diego, california.
ACLX Ratings Summary
ACLX Quant Ranking